Skip to Main Content

Paper Details

Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Circ Heart Fail
24
2021
Acute HF, Enalapril, HF, N, N-terminal pro-B type natriuretic peptide, NT-proBNP, Patients, Sacubitril, Valsartan, cardiovascular, cardiovascular death, enalapril, heart failure, hyperkalemia, hypotension, patients, renal function, sacubitril, valsartan
Author NameAffiliation
Eric J VelazquezYale School of Medicine
Eric J VelazquezYale School of Medicine
Eugene BraunwaldBrigham and Women's Hospital, Harvard Medical School
David A MorrowBrigham and Women's Hospital, Harvard Medical School
David A MorrowBrigham and Women's Hospital, Harvard Medical School
Adam D DeVoreDuke Clinical Research Institute, Duke University School of Medicine
  • 1 - 6

Datasets

Release 1.2